The ESG Weekly: The ESG of vaccines, and shareholders say JPM must talk climate
May 22, 2020
19:31
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
There are some promising COVID‐19 vaccines in early human trails, but we have some questions if they are successful: Who will own the patent? Who will distribute them? Who will be responsible if something goes wrong? And then we discuss the recent proxy battle at JPMorgan that ended with some interesting wins for climate activists.
Sustainability Now